The MedTEAM

Evidence

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration
Center for Mental Health Services
www.samhsa.gov
 The MedTEAM
Evidence

U.S. Department of Health and Human Services

Substance Abuse and Mental Health Services Administration
Center for Mental Health Services
Acknowledgments

This document was prepared for the Substance Abuse and Mental Health Services Administration
(SAMHSA) by the New Hampshire-Dartmouth Psychiatric Research Center under contract
number 280-00-8049 and Westat under contract number 270-03-6005, with SAMHSA, U.S.
Department of Health and Human Services (HHS). Pamela Fischer, Ph.D., and Crystal Blyler,
Ph.D., served as SAMHSA Government Project Officers.

Disclaimer

The views, opinions, and content of this publication are those of the authors and contributors
and do not necessarily reflect the views, opinions, or policies of the Center for Mental Health
Services (CMHS), SAMHSA, or HHS.

Public Domain Notice

All material appearing in this document is in the public domain and may be reproduced
or copied without permission from SAMHSA. Citation of the source is appreciated. However,
this publication may not be reproduced or distributed for a fee without the specific, written
authorization from the Office of Communications, SAMHSA, HHS.

Electronic Access and Copies of Publication

This publication may be downloaded or ordered at http://www.samhsa.gov/shin. Or, please call

SAMHSA’s Health Information Network at 1-877-SAMHSA-7 (1-877-726-4727) (English
and Español).

Recommended Citation

Substance Abuse and Mental Health Services Administration. MedTEAM: The Evidence. HHS Pub.
No. SMA-10-4548, Rockville, MD: Center for Mental Health Services, Substance Abuse and Mental
Health Services Administration, U.S. Department of Health and Human Services, 2010.

Originating Office

Center for Mental Health Services

Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Rockville, MD 20857

HHS Publication No. SMA-10-4548

Printed 2010
The Evidence

The Evidence introduces all stakeholders to the research

literature and other resources on Medication Treatment,
Evaluation, and Management (MedTEAM). This booklet
includes the following resources:
MedTEAM
 A selected bibliography for further reading;
 References for the citations presented throughout the KIT;
and
 Acknowledgements of KIT developers and contributors.

For references, see the booklet, The Evidence.

This KIT is part of a series of Evidence-Based Practices KITs created
by the Center for Mental Health Services, Substance Abuse and
Mental Health Services Administration, U.S. Department of Health
and Human Services.

This booklet is part of the MedTEAM KIT that includes a DVD,

CD-ROM, and seven booklets:

How to Use the Evidence-Based Practices KITs

Getting Started with Evidence-Based Practices

Building Your Program

Training Frontline Staff

Evaluating Your Program

The Evidence

Using Multimedia to Introduce Your EBP

What’s in The Evidence

Selected Bibliography.......................................................... 1
References........................................................................ 19
Acknowledgments............................................................. 23 MedTEAM
 The Evidence

Selected Bibliography

Stahl, S. M. (1999). Antipsychotic

Antipsychotic polypharmacy, Part 1: Therapeutic
polypharmacy option or dirty little secret? Journal
of Clinical Psychiatry, 60, 425-426.
Ananth, J., Parameswaran, S., &
Gunatilake, S. (2004). Antipsychotic Suzuki, T., Uchida, H., Watanabe, K.,
polypharmacy. Current Pharmaceutical Yagi, G., & Kashima, H. (2004).
Design, 10, 2231-2238. A clinical case series of switching
from antipsychotic polypharmacy
Canales, P. L., Olsen, J., Miller, A. L., to monotherapy with a second-
& Crismon, M. L. (1999). Role of generation agent on patients with
antipsychotic polypharmacotherapy chronic schizophrenia. Progress
in the treatment of schizophrenia. in Neuro-Psychopharmacology &
CNS Drugs, 12, 179-188. Biological Psychiatry, 28, 361-369.

Ito, H., Koyama, A., & Higuchi, T.

(2005). Polypharmacy and excessive
dosing: Psychiatrists’ perceptions of
antipsychotic drug prescription. British
Journal of Psychiatry, 187, 243-247.

The Evidence 1 Selected Bibliography

Electronic medical records (EMR) Fidelity scales

Major, L. F., & Turner, M. G. (2003). Assessing Bond, G. R., Miller, A. L., Taylor A., Tsai, J.,
the information management requirements Howard, P. B., El-Mallakh, P., et al. (2007).
for behavioral health providers. Journal A scale to assess fidelity to evidence-based
of Healthcare Management, 48, 323-333; principles of medication management for
discussion, 48, 334-335. schizophrenia. Schizophrenia Bulletin, 33, 469.

Howard, P. B., El-Mallakh, P., Miller, A. L.,

Web sites Rayens, M. K., Bond, G. R., Henderson, K.,
et al. (2009). Prescriber fidelity to a medication
http://psychiatry.mc.duke.edu
management evidence-based practice in the
The Clinical Research Information System treatment of schizophrenia. Psychiatric Services,
(CRIS) was developed over the past decade 60 (7), 929-935.
by the Duke University School of Medicine
Department of Psychiatry and Behavioral Taylor, A. C., Bond, G. R., Tsai, J., Howard, P. B.,
Sciences. Not only a true EMR, but also has El-Mallakh, P., Finnerty, M., et al. (2009). Scales
extensive research and clinical trial capabilities to evaluate quality of medication management:
that are being used by top centers in the country Development and psychometric properties.
and overseas. Administration and Policy in Mental Health
and Mental Health Services Research. Published
http://www.askesis.com online February 27, 2009. DOI 10.1007/s10488-
A link to the vendor for the PsychConsult 009-0209-z.
product, developed within and used by
Western Psychiatric Institute, among others.
Implementing evidence-based
http://www.capterra.com/mental-health-software
practices
An extensive list of EMR and other electronic
(scheduling, notes, prescriptions) software vendors. Drake, R. E., Goldman, H. H., Leff, H. S.,
Lehman, A. F., Dixon, L., Mueser, K. T., et al.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retr
(2001). Implementing evidence-based practices
ieve&db=PubMed&list_uids=14552101&dopt=Abstract
in routine mental health service settings.
A link for a 2003 paper that discusses Psychiatric Services, 52, 179-182.
assessing behavioral health agency needs
for EMR implementation. Goldman, H. H., Ganju, V., Drake, R. E., Gorman,
P., Hogan, M., Hyde, P. S., et al. (2001). Policy
implications for implementing evidence-based
practices. Psychiatric Services, 52, 1591-1597.

Sernyak, M. J. (2007). Implementation of

monitoring and management guidelines
for second-generation antipsychotics. Journal
of Clinical Psychiatry, 68(Suppl 4), 14-18.

Selected Bibliography 2 The Evidence

Torrey, W. C., Drake, R. E., Dixon, L., Burns, B. J., McEvoy, J. P., Scheifler, P. L., & Frances, A.,
Flynn, L., Rush, J., et al. (2001). Implementing (Eds.). (1999). The Expert Consensus Guideline
evidence-based practices for persons with severe Series: Treatment of schizophrenia 1999. Journal
mental illnesses. Psychiatric Services, 52, 45-50. of Clinical Psychiatry, 60(Suppl 11), 4-80.

Williams, T. L., Cerese, J., Cuny, J., & Sama, D. Mellman, T. A., Miller, A. L., Weissman, E. M.,
(2008). Outcomes of an initial set of standardized Crismon, M. L., Essock, S. M., & Marder,
performance measures for inpatient mental S. R. (2001). Evidence-based pharmacologic
health. Joint Commission Journal on Quality treatment for people with severe mental illness:
and Patient Safety, 34, 399-406. A focus on guidelines and algorithms. Psychiatric
Services, 52, 619-625.

Miller, A. L. (2004). PORT Treatment

Medication algorithms Recommendations. Schizophrenia Bulletin,
and guidelines 30, 601-604.

American Psychiatric Association Schizophrenia Moore, T. A., Buchanan, R. W., Buckley, P. F.,
Practice Guidelines. (2004). Retrieved from Chiles, J. A., Conley, R. R., Crismon, M. L., et al.
http://www.psychiatryonline.org (2007). The Texas medication algorithm project
antipsychotic algorithm for schizophrenia: 2006
Canadian Psychiatric Association. (2005, Nov.). update. Journal of Clinical Psychiatry, 68,
Clinical Practice Guidelines: Treatment of 1751-1762.
Schizophrenia. Canadian Journal of Psychiatry,
50(13 Suppl 1), 7S-57S. Texas Department of State Health Services, Texas
Medication Algorithm Project (TMAP) and
International Psychopharmacology Algorithm Texas Implementation of Medication Algorithms
Project. (2007). http://www.ipap.org (TIMA). (2007). Antipsychotic algorithm for the
treatment of schizophrenia. Available from
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., http://www.dshs.state.tx.us/mhprograms/TIMA.shtm
Dickerson, F. B., Dixon, L. B., Goldberg, R., et al.
(2004). The Schizophrenia Patient Outcomes
Research Team (PORT): Updated treatment
recommendations 2003. Schizophrenia Bulletin,
30, 193-217.

The Evidence 3 Selected Bibliography

 Gilbert, P. L., Harris, M. J., McAdams, L. A.,
Medications for schizophrenia & Jeste, D. V. (1995). Neuroleptic withdrawal
in schizophrenia patients: A review of the
Baldessarini, R. J., Gardener, D. M., & Garver, literature. Archives of General Psychiatry,
D. L. (1995). Conversions from clozapine to 52, 173-188.
other antipsychotic drugs [Letter to the editor].
Archives of General Psychiatry, 52, 1071-1072. Janicak, P. G., Davis, J. M., Preskorn, S. H.,
Ayd, F. J., Jr., Marder, S. R., & Pavuluri,
Bell, R., McLaren, A., Gaionos, J., and Copolov, M. N. (2006). Principles and Practice
D. (1998). The clinical use of plasma clozapine of Psychopharmacotherapy (4th ed.).
levels. Australian and New Zealand Journal of Baltimore: Lippincott, Williams & Wilkins.
Psychiatry, 32, 567-574.
Jayaram, M. B., Hosalli, P., & Stroup, T. S. (2006).
Buckley, P. F. (1999). The role of typical and Risperidone versus olanzapine for schizophrenia.
atypical antipsychotic medications in the Cochrane Database of Systematic Reviews, (2),
management of agitation and aggression. Journal Art. No.: CD005237. DOI: 10.1002/14651858.
of Clinical Psychiatry, 60(Suppl 10), 52-60. CD005237.pub2.

Buckley, P., Miller, A., Olsen, J., Garver, D., Miller, Kinghorn, W. A., & McEvoy, J. P. (2005).
D. D., & Csernansky, J. (2001). When symptoms Aripiprazole: Pharmacology, efficacy,
persist: Clozapine augmentation strategies. safety and tolerability. Expert Review
Schizophrenia Bulletin, 27, 615-628. of Neurotherapeutics, 5, 297-307.

Carnahan, R. M., Lund, B. C., & Perry, P. J. Lieberman, J. A., Safferman, A. Z., Pollack, S.,
(2001). Ziprasidone, A new atypical antipsychotic Szymanski, S., Johns, C., Howard, A., et al.
drug. Pharmacotherapy, 21, 717-730. (1994). Clinical effects of clozapine in chronic
schizophrenia: Response to treatment and
Chang, H. H., & Berman, I. (1999). Treatment predictors of outcome. American Journal
issues for consumers with schizophrenia of Psychiatry, 151, 1744-1752.
who have obsessive-compulsive symptoms.
Psychiatric Annals, 29, 529-532. Lindenmayer, J. P., & Khan, A. (2004).
Pharmacological treatment strategies
Conley, R. R., & Mahmoud, R. (2001). A for schizophrenia. Expert Review of
randomized double-blind study of risperidone Neurotherapeutics, 4, 705-723.
and olanzapine in the treatment of schizophrenia
or schizoaffective disorder. American Journal Lindenmayer, J. P., Khan, A., Iskander, A., Abad,
of Psychiatry, 158, 765-774. M. T., & Parker, B. (2007). A randomized
controlled trial of olanzapine versus haloperidol
Conley, R. R., Tamminga, C.A., Bartko, J. J., in the treatment of primary negative symptoms
Richardson, C., Peszke, M., Lingle, J., et al. and neurocognitive deficits in schizophrenia.
(1998). Olanzapine compared with chlorpromazine Journal of Clinical Psychiatry, 68, 368-379.
in treatment-resistant schizophrenia. American
Journal of Psychiatry, 155, 914-920.

Selected Bibliography 4 The Evidence

Luft, B., & Taylor, D. (2006). A review of atypical Siris, S. G. (2000). Depression in schizophrenia:
antipsychotic drugs versus conventional Perspective in the era of “atypical” antipsychotic
medication in schizophrenia. Expert Opinion agents. American Journal of Psychiatry, 157,
on Pharmacotherapy, 7, 1739-1748. 1379-1389.

Marder, S. R. (2000). Schizophrenia: Somatic Stroup, T. S., Lieberman, J. A., McEvoy, J. P.,
treatment. In B. J. Sadock and V. A. Sadock Swartz, M. S., Davis, S. M., Rosenheck, R. A.,
(Eds.), Comprehensive textbook of psychiatry et al. (2006). Effectiveness of olanzapine,
VII (pp. 1199-1210). Philadelphia: Lippincott, quetiapine, risperidone, and ziprasidone in
Williams & Wilkins: 1199-1210. patients with chronic schizophrenia following
discontinuation of a previous atypical
Meltzer, H. Y., & Bobo, W. V. (2006). Interpreting antipsychotic. American Journal of Psychiatry,
the efficacy findings in the CATIE study: 163, 611-622.
What clinicians should know. CNS Spectrums,
11(7 Suppl 7), 14-24. Stroup, T. S., Lieberman, J. A., McEvoy, J. P.,
Swartz, M. S., Davis, S. M., Capuano, G. A.,
Meyer, J. M. (2007). Antipsychotic safety and et al. (2007). Effectiveness of olanzapine,
efficacy concerns. Journal of Clinical Psychiatry, quetiapine, and risperidone in patients with
68(Suppl 14), 20-26. chronic schizophrenia after discontinuing
perphenazine: A CATIE study. American Journal
Miller, A. L., Dassori, A., Ereshefsky, L., & of Psychiatry, 164, 415-427.
Crismon, M. L. (2001). Recent issues and
developments in antipsychotic use. In D. L. Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-
Dunner & J. F. Rosenbaum (Eds.), Psychiatric Ibor, Jr., J. J., Okasha, A., Singh, B., et al. (2008).
clinics of North America annual of drug World Psychiatric Association Pharmacopsychiatry
therapy (pp. 209-235). Philadelphia: W. B. Section statement on comparative effectiveness
Saunders Company. of antipsychotics in the treatment of schizophrenia.
Schizophrenia Research, 100, 20-38.
Miller, A. L., McEvoy, J. P., Jeste, D., & Marder,
S. (2006). Treatment of chronic schizophrenia. Thompson, C. (1994). The use of high-dose
In J. A. Lieberman, T. S. Stroup, & D. O. Perkins antipsychotic medication. British Journal of
(Eds.), Textbook of schizophrenia (pp. 365- Psychiatry, 164, 448-458.
381). Arlington, VA: American Psychiatric
Publishing, Inc. Viguera, A. C., Baldessarini, R. J., Hegarty, J. D.,
van Kammen, D. P., & Tohen, M. (1997).
Reznik, I., & Sirota, P. (2000). Obsessive Clinical risk following abrupt and gradual
and compulsive symptoms in schizophrenia: withdrawal of maintenance neuroleptic
A randomized controlled trial with fluvoxamine treatment. Archives of General Psychiatry,
and neuroleptics. Journal of Clinical 54, 49-55.
Psychopharmacology, 20, 410-416.
Yen, Y.-C., Lung, F. W., & Chong, M. Y. (2004).
Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, Adverse effects of risperidone and haloperidol
M., Schwartz, B., Dorfman-Etrog, P. et al. treatment in schizophrenia. Progress in Neuro-
(1997). Sulpiride augmentation in people with Psychopharmacology & Biological Psychiatry,
schizophrenia partially responsive to clozapine. 28, 285-290.
A double-blind, placebo-controlled study. British
Journal of Psychiatry, 171, 569-573.

The Evidence 5 Selected Bibliography

 International Bibliographic Information on Dietary
Medication update Web sites Supplements (IBIDS).
and newsletters http://ods.od.nih.gov/Health_Information/IBIDS.aspx

Biological Therapies in Psychiatry. Journal Watch: Psychiatry.

http://www.btpnews.com http://psychiatry.jwatch.org

Child & Adolescent Psychiatry Alerts. MedlinePlus: Medicines.

http://www.alertpubs.com/child.htm http://www.nlm.nih.gov/medlineplus/medicines.html

Current Psychiatry. Psychiatry Drug Alerts.

http://www.currentpsychiatry.com http://www.alertpubs.com/Psych.htm

Epocrates. Online–Free drug and clinical Psychiatry Weekly.

reference for the web browser. http://www.psychiatryweekly.com
http://www.epocrates.com/products/online/index.html
Psychopharm Review (formerly International Drug
Evidence-Based Answers to Clinical Questions Therapy Newsletter).
for Busy Clinicians (2009). The Centre for http://www.lww.com/resources/cmeinfo/
Clinical Effectiveness, Southern Health, at the internationaldrugtherapy.html
Monash Institute of Health Services Research,
Melbourne, Australia. The Brown University Child and Adolescent
http://www.southernhealth.org.au/icms_docs/2145_ Psychopharmacology Update.
EBP_workbook.pdf http://www.wiley.com/WileyCDA/WileyTitle/
productCd-CPU.html
Food and Drug Administration: Drugs@FDA.
http://www.accessdata.fda.gov/scripts/cder/ The Brown University Geriatric
drugsatfda Psychopharmacology Update.
http://www.wiley.com/WileyCDA/WileyTitle/
Food and Drug Administration: Center for Drug productCd-GPU.html
Evaluation and Research.
http://www.fda.gov/cder/drug/default.htm The Brown University Psychopharmacology Update.
http://www.wiley.com/WileyCDA/WileyTitle/
Indiana University, Division of Clinical productCd-PU.html
Pharmacology: Drug Interaction Table
(Cytochrome P450 System). The Carlat Psychiatry Report.
http://medicine.iupui.edu/flockhart http://www.thecarlatreport.com

Selected Bibliography 6 The Evidence

 Marder, S. R., Essock, S. M., Miller, A. L.,
Quality of medication Buchanan, R. W., Davis, J. M., Kane, J. M.,
management and et al. (2002). The Mount Sinai conference
documentation on the pharmacotherapy of schizophrenia.
Schizophrenia Bulletin, 28, 5-16.
Adams, A. S., Soumerai, S. B., Lomas, J., & Ross-
Degnan, D. (1999). Evidence of self-report Owen, R. R., Thrush, C. R., Hudson, T. J., Mallory,
bias in assessing adherence to guidelines. S. R., Fischer, E. P., Clardy, J. A., et al. (2002).
International Journal for Quality in Health Using an explicit guideline-based criterion and
Care, 11, 187-192. implicit review to assess antipsychotic dosing
performance for schizophrenia. International
American Psychiatric Association. (2004). Practice Journal for Quality in Health Care, 14, 199-206.
guideline for the treatment of patients with
schizophrenia (2nd ed.). Arlington, VA: Author. Rush, A. J., Rago, W. V., Crismon, M. L., Toprac,
M. G., Shon, S. P., Suppes, T., et al. (1999).
Bollini, P., Pampallona, S., Nieddu, S., Bianco, M., Medication treatment for the severely and
Tibaldi, G., & Munizza, C. (2008). Indicators of persistently mentally ill: The Texas Medication
conformance with guidelines of schizophrenia Algorithm Project. Journal of Clinical
treatment in mental health services. Psychiatric Psychiatry, 60, 284-291.
Services, 59, 782-791.
Smith, T. E., & Docherty, J. P. (1998). Standards
Cradock, J., Young, A. S., et al. (2001). The accuracy of care and clinical algorithms for treating
of medical record documentation in schizophrenia. schizophrenia. Psychiatric Clinics of North
Journal of Behavioral Health Services and America, 21, 203-220.
Research, 28, 456-465.
Uttaro, T., Finnerty, M., White, T., Gaylor, R., &
Lehman, A. F. (1999). Improving treatment Shindelman, L. (2007). Reduction of concurrent
for persons with schizophrenia. Psychiatric antipsychotic prescribing practices through the
Quarterly, 70, 259-272. use of PSYCKES. Administration and Policy
in Mental Health and Mental Health Services
Lehman, A. F., Steinwachs, D. M., & the Co- Research, 34, 57-61.
Investigators of the PORT Project. (1998).
Translating research into practice: The Young, A. S., Sullivan, G., Burnam, M. A., &
schizophrenia PORT treatment recommendations. Brook, R. H. (1998). Measuring the quality of
Schizophrenia Bulletin, 24, 1-10. outpatient treatment for schizophrenia. Archives
of General Psychiatry, 55, 611-617.

The Evidence 7 Selected Bibliography

Racial and ethnic effects Recovery and remission
on medication management
Allott, P., Loganathan, L., & Fulford, K. W. M.
Frackiewicz, E. J., Sramek, J. J., Herrera, J. M., (2002). Discovering hope for recovery: A review
Kurtz, N.., & Cutler, N. R. (1997). Ethnicity of a selection of recovery literature, implications
and antipsychotic response. Annals of for practice and systems change. Canadian
Pharmacotherapy, 31, 1360-1369. Journal of Community Mental Health, 21, 13-33.

Leckband, S. G., Bishop, J. R., & Ellingrod, V. L. American Psychiatric Association (2005).
(2007). Pharmacogenomics in psychiatry. Journal Use of the concept of recovery: Position
of Pharmacy Practice, 20, 252-264. statement Arlington, VA: Author. Retrieved from
http://www.psych.org/Departments/EDU/

Malhotra, A. K., Murphy, G. M., & Kennedy, J. L. Library/APAOfficialDocumentsandRelated/

PositionStatements/200504.aspx
(2004). Pharmacogenetics of psychotropic drug
response. American Journal of Psychiatry, 161,
780-796. Andreasen, N. C., Carpenter, W. T., Kane, J. M.,
Lasser, R. A., Marder, S. R., & Weinberger,
Ng, C. H., Chong, S. A., Lambert, T., Fan, A., D. R. (2005). Remission in schizophrenia:
Hackett, L. P., & Mahendran, R. (2005). An Proposed criteria and rationale for consensus.
inter-ethnic comparison study of clozapine American Journal of Psychiatry, 162, 441–449.
dosage, clinical response, and plasma levels.
International Clinical Psychopharmacology, Anthony, W., Rogers, E. S., & Farkas, M. (2003).
20, 163-168. Research on evidence-based practices: Future
directions in an era of recovery. Community
U.S. Department of Health and Human Services. Mental Health Journal, 39, 101-114.
(2001). Mental health: Culture, race, and
ethnicity— A supplement to mental health: Campbell-Orde, T., Chamberlin, J., Carpenter,
A report of the Surgeon General. Rockville, J., & Leff, H. S. (Eds.). (2005). Measuring the
MD: U.S. Department of Health and Human promise: A compendium of recovery measures
Services, Substance Abuse and Mental Health (Vol. II). (Publication No. 55). Cambridge, MA:
Services Administration, Center for Mental The Evaluation Center @ Human Services
Health Services. Research Institute.

Center for Mental Health Services. (2005).

National consensus statement on mental health
recovery (Publication No. SMA-05-4129).
Rockville, MD: Substance Abuse and
Mental Health Services Administration, U.S.
Department of Health and Human Services.

Selected Bibliography 8 The Evidence

Copeland, Mary Ellen. (1997). Wellness Recovery Ralph, R. O., Kidder, K., & Phillips, D. (2000).
Action Plan. West Dummerston, VT: Peach Press. Can we measure recovery? A compendium
of recovery and recovery-related instruments
Davidson, L., Schmutte, T., Dinzeo, T., & Andres- (Publication No. 43). Cambridge, MA:
Hyman, R. (2008). Remission and recovery The Evaluation Center @Human Services
in schizophrenia: Practitioner and patient Research Institute.
perspectives. Schizophrenia Bulletin, 34:5-8.
Ralph, Ruth O. (2000). Review of recovery
Del Vecchio, P., & Blyler, C. R. (2009). Identifying literature: A synthesis of a sample of recovery
critical outcomes and setting priorities for Literature 2000. Alexandria, VA: National
mental health services research. In J. Wallcraft, Association of State Mental Health Program
B. Schrank, & M. Amering (Eds.), Handbook Directors, National Technical Assistance Center
of service user involvement in mental health for State Mental Health Planning.
research (pp. 99-112). Hoboken, NJ:
Wiley-Blackwell. Ralph, R. O., Lambert, D., & Kidder, K. A.
(2002). Recovery perspective and evidence-
Dumont, J. M., Ridgway, P., Onken, S. J., Dornan, based practice for people with serious mental
D. H., & Ralph, R. O. (2006). Mental health illness: A guideline developed for the Behavioral
recovery: What helps and what hinders? Health Recovery Management Project. An
A national research project for the development Initiative of Fayette Companies, Peoria, IL;
of recovery facilitating system performance Chestnut Health Systems, Bloomington,
indicators. Alexandria, VA: National Association IL; and the University of Chicago Center
of State Mental Health Program Directors, for Psychiatric Rehabilitation. Retrieved
National Technical Assistance Center for State from http://www.bhrm.org/guidelines/Ralph%20
Mental Health Planning. Recovery.pdf

Evaluation Center @ Human Services Research Ridgway, P. (2001). Restorying psychiatric

Institute. (2007). Addendum to measuring the disability: Learning from first person recovery
promise: A compendium of recovery measures, narratives. Psychiatric Rehabilitation Journal,
Volume II. Cambridge, MA: Author. 24, 335-344.

Farkas, M., Gagne, C., Anthony, W., & Sowers, W. (2005). Transforming systems of
Chamberlin, J. (2005). Implementing recovery care: The American Association of Community
oriented evidence based programs: Identifying Psychiatrists Guidelines for Recovery Oriented
the critical dimensions. Community Mental Services. Community Mental Health Journal, 41,
Health Journal, 41, 141-158. 757-774.

Jacobson, N. (2004). In recovery: The making of Young, S. L., & Ensing, D. S. (1999). Exploring
mental health policy. Nashville, TN: Vanderbilt recovery from the perspective of people with
University Press. psychiatric disabilities. Psychiatric Rehabilitation
Journal, 22, 219-231.
Kane, J. M. (2008). An evidence-based strategy for
remission in schizophrenia. Journal of Clinical
Psychiatry, 69(Suppl 3), 25-30.

The Evidence 9 Selected Bibliography

 Deegan, P. E., Rapp, C., Holter, M., & Riefer, M.
Shared decisionmaking (2008). Best practices: A program to support
and adherence shared decision making in an outpatient
psychiatric medication clinic. Psychiatric
Adams, N., & Grieder, D. (2004). Treatment Services, 59, 603-605.
planning for person-centered care: The road to
mental health and addiction recovery. Burlington, Elwyn, G., Edwards, A., Gwyn, R., & Grol, R.
Massachusetts: Elsevier Academic Press. (1999). Towards a feasible model for shared
decision-making: Focus group study with general
Adams, J., & Scott, J. (2000). Predicting practice registrars. BMJ, 319, 753-756.
medication adherence in severe mental
disorders. Acta Psychiatrica Scandinavica, Fallon, I. R. H. (1984). Developing and
101, 119-124. maintaining adherence to long-term drug-taking
regimens. Schizophrenia Bulletin, 10, 412-417.
Agarwal, M. R., Sharma, V. K., Kishore Kumar,
K. V, & Lowe, D. (1998). Non-compliance Frank, A. F., & Gunderson, J. G. (1990). The role
with treatment in patients suffering from of the therapeutic alliance in the treatment
schizophrenia: A study to evaluate possible of schizophrenia: Relationship to course and
contributing factors. International Journal outcome. Archives of General Psychiatry, 47,
of Social Psychiatry, 44, 92-106. 228-236.

Byerly, M. J., Nakonezny, P. A., & Rush, A. J. Frosch, D. L., & Kaplan, R. M. (1999). Shared
(2008). The Brief Adherence Rating Scale decision-making in clinical medicine: Past
(BARS) validated against electronic monitoring research and future directions. American Journal
in assessing the antipsychotic medication of Preventive Medicine, 17, 285-294.
adherence of outpatients with schizophrenia
and schizoaffective disorder. Schizophrenia Garavan, J., Browne, S. Gervin, M., Lane,
Research, 100, 60-69. A., Larkin, C., & O’Callaghan, E. (1998).
Compliance with neuroleptic medication
Charles, C., Gafni, A., & Whelan, T. (1997). Shared in outpatients with schizophrenia; relationship
decision-making in the medical encounter: What to subjective response to neuroleptics; attitudes
does it mean? (Or it takes at least two to tango). to medication and insight. Comprehensive
Social Science & Medicine, 44, 681-692. Psychiatry, 39, 215-219.

Corrigan, P. W., Liberman R. P., & Engel, J. D. Kelly, G. R., & Scott, J. A. (1990). Medication
(1990). From noncompliance to collaboration compliance and health education among
in the treatment of schizophrenia. Hospital & outpatients with chronic mental disorders.
Community Psychiatry, 41, 1203-1211. Medical Care, 28, 1181-1197.

Cramer, J. A., & Rosenheck, R. (1998). Kemp, R., Kirov, G., Everitt, B., Hayward, P., &
Compliance with medication regimens for mental David, A. (1998). Randomised controlled trial of
and physical disorders. Psychiatric Services, 49, compliance therapy–18 month follow-up. British
196-201. Journal of Psychiatry, 172, 413-419.

Selected Bibliography 10 The Evidence

Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, Tay, S. E. (2007). Compliance therapy: An
S. G., & Jeste, D. V. (2002). Prevalence of and intervention to improve inpatients’ attitudes
risk factors for medication nonadherence in toward treatment. Journal of Psychosocial
patients with schizophrenia: A comprehensive Nursing and Mental Health Services, 45, 29-37.
review of recent literature. Journal of Clinical
Psychiatry, 63, 892-909. Uzenoff, S. R., Perkins, D. O., Hamer, R. M.,
Wiesen, C. M., & Penn, D. L. (2008). A
Masand, P. S., & Narasimhan, M. (2006). preliminary trial of adherence-coping-education
Improving adherence to antipsychotic (ACE) therapy for early psychosis. Journal of
pharmacotherapy. Current Clinical Nervous and Mental Disease, 196, 572-575.
Pharmacology, 1, 47-56.
Van Putten, T., & May, R. A. (1978). Subjective
Macpherson, R., Jerrom, B., & Hughes, A. (1996). response as a predictor of outcome in
A controlled study of education about drug pharmacotherapy. Archives of General
treatment in schizophrenia. British Journal Psychiatry, 35, 477-480.
of Psychiatry, 168, 709-717.
Van Putten, T., May, P. R. A., Marder, S. R., &
Nosé, M., Barbui, C., & Tansella, M. (2003). Wittmann, L. A. (1981). Subjective response
How often do patients with psychosis fail to to antipsychotic drugs. Archives of General
adhere to treatment programmes? A systematic Psychiatry, 38, 187-190.
review. Psychological Medicine, 33, 1149-1160.
Published online 9/27/03. Available from Velligan, D. I., Diamond, P. M., Mintz, J., Maples,
http://journals.cambridge.org N., Li, X., Zeber, J., et al. (2008). The use of
individually tailored environmental supports
Olfson, M., Mechanic, D., Hansell, S., Boyer, to improve medication adherence and outcomes
C. A., Walkup, J., & Weiden, P. J. (2000). in schizophrenia. Schizophrenia Bulletin, 34,
Predicting medication noncompliance after 483-493.
hospital discharge among patients with
schizophrenia. Psychiatric Services, 51, 216-222. Velligan, D. I., Lam, F., Ereshefsky, L., & Miller,
A. L. (2003). Psychopharmacology: Perspectives
Perkins, D. O., Johnson, J. L., Hamer, R. M., on medication adherence and atypical
Zipursky, R. B., Keefe, R. S., Centorrhino, antipsychotic medications. Psychiatric Services,
F., et al. (2006). Predictors of antipsychotic 54, 665-667.
medication adherence in patients recovering
from a first psychotic episode. Schizophrenia Velligan, D., Lam, Y. W. F., Glahn, D. C., Barrett,
Research, 83, 53-63. J. A., Maples, N. J., Ereshefsky, L., et al.
(2006). Defining and assessing adherence to
Ruscher, S. M., de Wit, R., & Mazmanian, D. oral antipsychotics: A review of the literature.
(1997). Psychiatric patients’ attitudes about Schizophrenia Bulletin, 32, 724-742.
medication and factors affecting noncompliance.
Psychiatric Services, 48, 82-85. Velligan, D. I., Wang, M., Diamond, P., Glahn,
D. C., Castillo, D., Bendle, S., et al. (2007).
Stevenson, F. A., Barry, C. A., Britten, N., Barber, Relationships among subjective and objective
N., & Bradley, C. P. (2000). Doctor-patient measures of adherence to oral antipsychotic
communication about drugs: The evidence medications. Psychiatric Services, 58, 1187-1192.
for shared decision-making. Social Science
& Medicine, 50, 829-840.

The Evidence 11 Selected Bibliography

 Hummer, M., & Huber, J. (2004).
Side effects of antipsychotic Hyperprolactinaemia and antipsychotic therapy
medication in schizophrenia. Current Medical Research &
Opinion, 20, 189-197.
American Diabetes Association Clinical Practice
Recommendations 2009. (2009). Diabetes Care, Iqbal, M. M., Rahman, A., Husain, Z., Mahmud,
32, S1-97. S. Z., Ryan, W. F., & Feldman, J. M. (2003).
Clozapine: A clinical review of adverse effects
American Diabetes Association, American and management. Annals of Clinical Psychiatry,
Psychiatric Association, American Association 15, 33-48.
of Clinical Endocrinologists, & North American
Association for the Study of Obesity. (2004). Juvonen, H., Reunanen, A., Haukka, J., Mukonen,
Consensus development conference on M. Suvisaari, J., Arajärvi, R., et al. (2007).
antipsychotic drugs and obesity and diabetes. Incidence of schizophrenia in a nationwide
Diabetes Care, 27, 596-601. cohort of patients with type 1 diabetes mellitus.
Archives of General Psychiatry, 64, 894-899.
Birkenaes, A. B., Birkeland, K. I., Engh, J. A.,
Færden, A., Jonsdottir, H., Ringen, P. A., Kennedy, A., Tapp, A., Kelly, W. S., Kilzieh,
et al. (2008). Dyslipidemia independent of N., & Wood, A. E. (2006). Abstinence,
body mass in antipsychotic-treated patients anticipation, reduction, and treatment (AART):
under real-life conditions. Journal of Clinical A stepwise approach to the management of
Psychopharmacology, 28, 132-137. atypical antipsychotic side effects. Essential
Psychopharmacology, 7, 1-14.
Byerly, M., Suppes, T., Tran, Q. V., & Baker, R. A.
(2007). Clinical implications of antipsychotic- Kleinberg, D. L., Davis, J. M., de Coster,
induced hyperprolactinemia in patients R., Van Baelan, B., & Brecher, M. (1999).
with schizophrenia spectrum or bipolar Prolactin levels and adverse effects in patients
spectrum disorders: Recent developments treated with risperidone. Journal of Clinical
and current perspectives. Journal of Clinical Psychopharmacology, 19, 57-61.
Psychopharmacology, 27, 639-661.
Lamberti, J. S., Costea, G. O., Olson, D., Crilly,
Drici, M. D., & Priori, S. (2007) Cardiovascular J. F., Maharaj, K., Tu, X., et al. (2005). Diabetes
risks of atypical antipsychotic drug treatment. mellitus among outpatients receiving clozapine:
Pharmacoepidemiology & Drug Safety, 16, 882- Prevalence and clinical-demographic correlates.
890. Journal of Clinical Psychiatry, 66, 900-906.

Glassman, A. H., & Bigger, J. T. (2001). Leslie, D. L., & Rosenheck, R. A. (2004).
Antipsychotic drugs: Prolonged QTC interval, Incidence of newly diagnosed diabetes
torsade de pointes, and sudden death. American attributable to atypical antipsychotic
Journal of Psychiatry, 158, 1774-1782. medications. American Journal of Psychiatry,
161, 1709-1711.
Henderson, D. C., Nguyen, D. D., Copeland,
P. M., Hayden, D. L., Borba, C. P., Louie, P. M., Malhotra, S., & McElroy, S. L. (2002). Medical
et al. (2005). Clozapine, diabetes mellitus, management of obesity associated with mental
hyperlipidemia, and cardiovascular risks and disorders. Journal of Clinical Psychiatry,
mortality: Results of a 10-year naturalistic study. 63(Suppl 4), 24-32.
Journal of Clinical Psychiatry, 66, 1116-1121.

Selected Bibliography 12 The Evidence

Melkersson, K. I., Dahl, M. L., & Hulting, Newcomer, J. W., Haupt, D. W., Fucetola, R.,
A. L. (2004). Guidelines for prevention and Melson, A. K., Schweiger, J. A., Cooper, B. P.,
treatment of adverse effects of antipsychotic et al. (2002). Abnormalities in glucose regulation
drugs on glucose-insulin homeostasis and lipid during antipsychotic treatment of schizophrenia.
metabolism. Psychopharmacology, 175, 1-6. Archives of General Psychiatry, 59, 337-345.

Mortensen, P. B., and Eaton, W. W. (2008). Parks J., Svendsen, D., Singer, P., & Foti, M. E.
Diabetes mellitus and schizophrenia. (Eds.) (2006). Morbidity and mortality in
Archives of General Psychiatry, 65, 237-238. people with serious mental illness. [Thirteenth
in a series of technical reports.] Alexandria,
Murashita, M., Inoue, T., Kusumi, I., Nakagawa, VA: National Association of State Mental
S., Itoh, K., Tanaka, T., et al. (2007). Glucose Health Program Directors (NAS. H.D)
and lipid metabolism of long-term risperidone Medical Directors Council Available from
monotherapy in patients with schizophrenia. http://www.nasmhpd.org
Psychiatry and Clinical Neurosciences, 61,
54‑58. Reinstein, M. J., Sirotovskaya, L. A., Jones, L. E.,
Mohan, S., & Chasanov, M. A. (1999). Effect
Nakajima, M., Terao, T., Iwata, N., & Nakamura, J. of clozapine-quetiapine combination therapy
(2005). Switching female schizophrenic patients on weight and glycaemic control: Preliminary
to quetiapine from conventional antipsychotic findings. Clinical Drug Investigations,
drugs: Effects on hyperprolactinemia. 18, 99-104.
Pharmacopsychiatry, 38, 17-19.
Shirzadi, A. A., & Ghaemi, S. N. (2006). Side
Nasrallah, H. A., Meyer, J. M., Goff, D. C., effects of atypical antipsychotics: Extrapyramidal
McEvoy, J. P., Davis, S. M, Stroup, T. S., et al. symptoms and the metabolic syndrome. Harvard
(2006). Low rates of treatment for hypertension, Review of Psychiatry, 14, 152-164.
dyslipidemia and diabetes in schizophrenia: Data
from the CATIE schizophrenia trial sample at Srihari, V. H., Tek, C., Chwastiak, L. A., Woods,
baseline. Schizophrenia Research, 86, 15-22. S. W., & Steiner, J. L. (2007). Best practices:
Surveillance and management of diabetes in a
CMHC Population. Psychiatric Services, 58,
1151-1153.

The Evidence 13 Selected Bibliography

 Byerly, M. J., Weber, M. T., Brooks, D. L., Snow,
Special topics L. R., Worley, M. A., & Lescoufleur, E., et
al. (2001). Antipsychotic medications and the
Altshuler, L., Hendrick, V., & Cohen, L. S. (1998). elderly: Effects on cognition and implications
Course of mood and anxiety disorders during for use. Drugs & Aging, 18, 45-61.
pregnancy and the postpartum period. Journal of
Clinical Psychiatry, 59(Suppl 2), 29-33. Centre for Addiction and Mental Health (CAMH).
(2007). Psychotropic medications and other
Altshuler, L. L, Cohen L., Szuba, M. P., Burt, V. K., substances during pregnancy and lactation:
Gitlin, M., & Mintz, J. (1996). Pharmacologic A handbook for health care providers. Toronto,
management of psychiatric illness during Ontario, Canada: Author. Available from
pregnancy: Dilemmas and guidelines. American http://www.camh.net/Publications/Resources_for_
Journal of Psychiatry, 153, 592-606. Professionals/Pregnancy_Lactation/index.html

Altshuler, L. L., Cohen, L. S., Moline, M. L., Chambers, C. (1996). Birth outcomes in pregnant
Kahn, D. A., Carpenter, D., & Docherty, J. P. women taking fluoxetine. New England Journal
(2001). Treatment of depression in women of Medicine, 335, 1010-1015.
(Consensus Guideline Series). Postgraduate
Medicine (special report), 1-107. Cohen, L. S., & Rosenbaum, J. F. (1998).
Psychotropic drug use during pregnancy:
American Academy of Pediatrics, Committee on Weighing the risks. Journal of Clinical
Drugs. (2000). Use of psychoactive medication Psychiatry, 59(Suppl 2), 18-28.
during pregnancy and possible effects on the
fetus and newborn. Pediatrics, 105, 880-887. Craig, M., & Abel, K. (2001). Prescribing for
psychiatric disorders in pregnancy and lactation.
Arango, C., Parellada, M., & Moreno, D. M. Best Practice & Research Clinical Obstetrics &
(2004). Clinical effectiveness of new generation Gynaecology, 15, 1013-1030.
antipsychotics in adolescent patients.
European Neuropsychopharmacology, 14(Suppl D. V.ne, C. L., & Nemeroff, C. B. (1999).
4), S471-479. Psychotropic drug interactions. In R. G.
Robinson and W. R. Yates (Eds.), Psychiatric
Briggs, G. G., Freeman, R. K., & Yaffe, S. J. treatment of the mentally ill (pp. 523-543).
(2008). Drugs in pregnancy and lactation: New York: Marcel Dekker, Inc.
A reference guide to fetal and neonatal
risk, (8th ed). Philadelphia: Lippincott, Ernst, C. L., & Goldberg, J. F. (2002). The
Williams & Wilkins. reproductive safety profile of mood stabilizers,
atypical antipsychotics, and broad-spectrum
Briggs Update: Drugs in Pregnancy psychotropics. Journal of Clinical Psychiatry,
and Lactation. Available from 63(Suppl 4), 42-55.
http://www.briggsdrugsinpregnancy.com
Gold, L. H. (2000). Use of psychotropic
Bupropion Pregnancy Registry Final Report. (2008). medication during pregnancy: Risk management
A project of Glaxo-SmithKline. Available from guidelines. Psychiatric Annals, 30, 421-432.
http://pregnancyregistry.gsk.com/bupropion.html

Selected Bibliography 14 The Evidence

Goldstein, D. J., & Corbin, L. A. (2000). Mintzer, J., & Targum, S. D. (2003). Psychosis
Olanzapine-exposed pregnancies and in elderly patients: Classification and
lactation: Early experience. Journal of Clinical pharmacotherapy. Journal of Geriatric
Psychopharmacology, 20, 399-403. Psychiatry and Neurology, 16, 199-206.

Ito, S. (2000). Drug therapy for breast-feeding Mortola, J. F. (1989). The use of psychotropic
women. New England Journal of Medicine, 343, agents in pregnancy and lactation. Psychiatric
118-126; erratum, 343, 1348. Clinics of North America, 12, 69-87.

Koren, G., Cohen, T., Chitayat, D., Kapur, B., Newport, D. J., Calamaras, M. R., D. V.ne, C. L.,
Remington, G., Reid, D. M., et al. (2002). Use of Donovan, J., Beach, A. J., Winn, S., et al. (2007).
atypical antipsychotics during pregnancy and the Atypical antipsychotic administration during
risk of neural tube defects in infants. American late pregnancy: Placental passage and obstetrical
Journal of Psychiatry, 159, 136-137. outcomes. American Journal of Psychiatry, 164,
1214-1220.
Lamotrigine Pregnancy Registry. A
project conducted by Glaxo-SmithKline. Nonacs, R., & Cohen, L. S. (1998). Postpartum
http://pregnancyregistry.gsk.com/lamotrigine.html mood disorders: Diagnosis and treatment
guidelines. Journal of Clinical Psychiatry,
Lane, H. Y., Jann, M. W., Chang, Y. C., Chiu, 59(Suppl 2), 34-40.
C. C., Huang, M. C., Lee, S. H., et al. (2001).
Repeated ingestion of grapefruit juice does Nulman, I., Rovet, J., Stewart, D. E., Wolpin,
not alter clozapine’s steady-state plasma levels, J., Gardner, H. A., & Theis, J. G. W. (1997).
effectiveness, and tolerability. Journal of Clinical Neurodevelopment of children exposed in utero
Psychiatry, 62, 812-817. to antidepressant drugs. New England Journal
of Medicine, 336, 258-262.
Llewellyn, A., & Stowe, Z. N. (1998). Psychotropic
medications in lactation. Journal of Clinical Ordean, A., Midmer, D., Graves, L., Payne,
Psychiatry, 59(Suppl 2), 41-52. S., Hunt, G., & the PRIMA Group. (2008).
Pregnancy-Related Issues in the Management
Masand, P. S., & Gupta, S. (2003). Long-acting of Addictions (PRIMA). A reference for care
injectable antipsychotics in the elderly: providers. Ontario, Canada: University of
Guidelines for effective use. Drugs & Aging, Toronto, Department of Family and Community
20, 1099-1110. Medicine, Retrieved from
http://www.addictionpregnancy.ca
McCarthy, R. H. (1994). Seizures following
smoking cessation in a clozapine responder. Organization of Teratology Information Specialists.
Pharmacopsychiatry, 27, 210-11. http://otispregnancy.org

McKenna, K., Koren, G., Tetelbaum, M., Wilton, L. Patton, S. W., Misri, S., Corral, M. R., Perry,
Shakir, S., Diav-Citrin, O., et al. (2005). Pregnancy K. F., and Kuan, & A. F. (2002). Antipsychotic
outcome of women using atypical antipsychotic medication during pregnancy and lactation in
drugs: A prospective comparative study. Journal women with schizophrenia: Evaluating the risk.
of Clinical Psychiatry, 66, 444-449. Canadian Journal of Psychiatry, 47, 959-965.

The Evidence 15 Selected Bibliography

Drugs in Pregnancy and Breastfeeding.
[Web page]. http://www.perinatology.com/ Symptom assessment
exposures/druglist.htm
Bell, M., Fiszdon, J., Richardson, R. Lysaker,
Schou, M. (1990). Lithium treatment during P., & Bryson, G. (2007). Are self-reports
pregnancy, delivery, and lactation: An update. valid for schizophrenia patients with poor
Journal of Clinical Psychiatry, 51, 410-413. insight? Relationship of unawareness of illness
to psychological self-report instruments.
Toren, P., Ratner, S., Laor, N., & Weizman, A. Psychiatry Research, 151, 37-46.
(2004). Benefit-risk assessment of atypical
antipsychotics in the treatment of schizophrenia Niv, N., Cohen, A. N., Mintz, J., Ventura, J., &
and comorbid disorders in children and Young, A.S. (2007). The validity of using patient
adolescents. Drug Safety, 27, 1135-1156. self-report to assess psychotic symptoms in
schizophrenia. Schizophrenia Research, 90,
Toxicology Data Network: LactMed: Drugs 245-250.
and Lactation Database. Available from
http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT Rush, A. J., Jr., First, M. B., & Blacker, D. (Eds.).
(2008). Handbook of psychiatric measures
Trixler, M., Gáti, A., Fekete, S., & Tényi, T. (2005). (2nd ed.). Arlington, VA: American Psychiatric
Use of antipsychotics in the management of Publishing, Inc.
schizophrenia during pregnancy. Drugs, 65,
1193-1206. Sajatovic, M., & Ramirez, L. F. (2003). Rating
scales in mental health (2nd ed.). Hudson, Ohio:
Viguera, A. C., Cohen, L. S., Baldessarini, R. J., & Lexi-Comp, Inc.
Nonacs, R. (2002). Managing bipolar disorder
during pregnancy: Weighing the risks and
benefits. Canadian Journal of Psychiatry, 47,
426-436.

Yaeger, D., Smith, H. G., & Altshuler, L. L.

(2006). Atypical antipsychotics in the treatment
of schizophrenia during pregnancy and the
postpartum. American Journal of Psychiatry,
163, 2064-2070.

Yogev, Y., Ben-Haroush, A., & Kaplan, B. (2002).

Maternal clozapine treatment and decreased
fetal heart rate variability. International Journal
of Gynecology & Obstetrics, 79, 259-260.

Selected Bibliography 16 The Evidence

 McEvoy, J. P., Lieberman, J. A., Stroup, T. S.,
Treatment-resistant Davis, S. M., Meltzer, H. Y., Rosenheck, R. A.,
schizophrenia et al. (2006). Effectiveness of clozapine versus
olanzapine, quetiapine, and risperidone in
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. patients with chronic schizophrenia who did
(1988). Clozapine for the treatment-resistant not respond to prior atypical antipsychotic
schizophrenic: A double-blind comparison with treatment. American Journal of Psychiatry,
chlorpromazine. Archives of General Psychiatry, 163, 600-610.
45, 789-796.
Rosenheck, R., Cramer, J., Xu, W., Thomas, J.,
Kelly, D. L., Conley, R. R., Richardson, C. M., Henderson, W., Frisman, L., et al. (1997).
Tamminga, C. A., & Carpenter, W. T. (2003). A comparison of clozapine and haloperidol
Adverse effects and laboratory parameters of in hospitalized patients with refractory
high-dose olanzapine vs. clozapine in treatment- schizophrenia. Department of Veterans
resistant schizophrenia. Annals of Clinical Affairs Cooperative Study Group on Clozapine
Psychiatry, 15, 181-186. in Refractory Schizophrenia. New England
Journal of Medicine, 337, 809-815.
Lerner, V., Libov, I., Kotler, M., & Strous,
R. D. (2004). Combination of “atypical”
antipsychotic medication in the management
of treatment-resistant schizophrenia and
schizoaffective disorder. Progress in Neuro-
Psychopharmacology & Biological Psychiatry,
28, 89-98.

The Evidence 17 Selected Bibliography

 The Evidence

References

The following list includes the references for all citations in the KIT.

Arranz, M. J., & de Leon, J. Bond, G. R., & Salyers, M. P. (2004).

(2007). Pharmacogenetics and Prediction of outcome from the
pharmacogenomics of schizophrenia: Dartmouth Assertive Community
A review of last decade of research. Treatment Fidelity Scale. CNS
Molecular Psychiatry, 12, 707-747. Spectrums, 9, 937-942.

Bauer, M. S. (2002). A review of Cabana, M. D., Rand, C. S., Powe,

quantitative studies of adherence N. R., Wu, A. W., Wilson, M. H.,
to mental health clinical practice Abboud, P. A. C., et al. (1999).
guidelines. Harvard Review of Why don’t physicians follow clinical
Psychiatry, 10, 138-153. practice guidelines? A framework for
improvement. Journal of the American
Becker, D. R., Bond, G. R., McCarthy, Medical Association, 282, 1458-1465.
D., Thompson, D., Xie, H., McHugo,
G. J., et al. (2001). Converting day Carbamazepine package insert. See
treatment centers to supported http://www.pharma.us.novartis.com/
employment programs in Rhode Island. product/pi/pdf/tegretol.pdf
Psychiatric Services, 52, 351-357.

The Evidence 19 References

Cradock, J., Young, A. S., & Sullivan, G. (2001). Katon, W., Von Korff, M., Lin, E., Walker,
The accuracy of medical record documentation E., Simon, G. E., Bush, T., et al. (1995).
in schizophrenia. Journal of Behavioral Health Collaborative management to achieve treatment
Services & Research, 28, 456-465. guidelines: Impact on depression in primary
care. Journal of the American Medical
Drake, R. E., Bond, G. R., & Rapp, C. A. (2006). Association, 273, 1026-1031.
Explaining the variance within supported
employment programs: Comment on “what Lehman, A. F., & Steinwachs, D. M. (1998).
predicts supported employment outcomes?” Patterns of usual care for schizophrenia:
Community Mental Health Journal, 42, 315-318. Initial results from the Schizophrenia Patient
Outcomes Research Team (PORT) Client
Frackiewicz, E. J., Herrera, J. M., Sramek, Survey. Schizophrenia Bulletin, 24, 11-20.
J. J., Collazo, I. Y., & Lawson, W. B. (2002).
Risperidone in the treatment of Hispanic Lieberman, J. A., Stroup, T. S., McEvoy, J. P.,
inpatients with schizophrenia: A pilot study. Swartz, M. S., Rosenheck, R., Perkins, D. O.,
Psychiatry 65(4): 371-374. et al. (2005). Effectiveness of antipsychotic drugs
in patients with chronic schizophrenia. New
Ferris, F. D., & Librach, S. L. (2005). Models, England Journal of Medicine, 353, 1209-1223.
standards, guidelines. Clinics in Geriatric
Medicine, 21, 17-44. Lin, K. M., & Finder, E. (1983). Neuroleptic
dosage for Asians. American Journal of
Ganju, V. (2004, June). Evidence-based practices: Psychiatry, 140, 490-491.
Responding to the challenge. Presented at
the NAS. H.D Commissioner’s Meeting, San Lindenmayer, J. P., Volavka, J., Lieberman, J.,
Francisco, CA. Sheitman, B., Citrome, L., Chakos, M., et al.
(2001). Olanzapine for schizophrenia refractory
Howard, P. B., El-Mallakh, P., Miller, A. L., to typical and atypical antipsychotics: An open-
Rayens, M. K., Bond, G. R., Henderson, K., label, prospective trial. Journal of Clinical
et al. (2009). Prescriber fidelity to a medication Psychopharmacology, 21, 448-453.
management evidence-based practice in the
treatment of schizophrenia. Psychiatric Services, Marder, S. R., Essock, S. M., Miller, A. L.,
60, 929-935. Buchanan, R. W., Davis, J. M., Kane, J. M.,
et al. (2002). The Mount Sinai Conference
Hyde, P. S., Falls, K., Morris, J. A., & Schoenwald, on the pharmacotherapy of schizophrenia.
S. K. (2003). Turning knowledge into practice: Schizophrenia Bulletin, 28, 5-16.
A manual for behavioral health administrators
and practitioners about understanding and Marder, S. R., Essock, S. M., Miller, A. L.,
implementing evidence-based practices. Boston: Buchanan, R. W., Casey, D. E., Davis, J. M.,
Technical Assistance Collaborative. Available et al. (2004). Physical health monitoring of
from http://www.tacinc.org patients with schizophrenia. American Journal of
Psychiatry, 161, 1334-1349.
Institute of Medicine. (2006). Improving the quality
of health care for mental and substance-use
conditions: Quality Chasm Series. Washington,
DC: National Academy of Sciences.

References 20 The Evidence

Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, Sackett, D. L., Rosenberg, W. M. C., Gray,
K., Chen, Y., Ertugrul, A., et al. (2008). J. A. M., Haynes, A. B., & Richardson, W. S.
A randomized, double-blind comparison (1996). Evidence based medicine: What it is and
of clozapine and high-dose olanzapine in what it isn’t. British Medical Journal, 312, 71-72.
treatment-resistant patients with schizophrenia.
Journal of Clinical Psychiatry, 69, 274-285. Sajatovic, M., & Ramirez, L. F. (2003). Rating
Scales in Mental Health (2nd ed.). Hudson,
Monash Institute of Health Services Research Ohio: Lexi-Comp, Inc.
(2006). Evidence-Based Answers to Clinical
Questions for Busy Clinicians. The Centre for Sernyak, M. J., Dausey, D., Desai, R.,
Clinical Effectiveness, Melbourne, Australia. & Rosenheck, R. (2003). Prescribers’
nonadherence to treatment guidelines for
National Advisory Mental Health Council schizophrenia when prescribing neuroleptics.
Workgroup on Child and Adolescent Mental Psychiatric Services, 54, 246-248.
Health Intervention Development and
Deployment. (2001). Blueprint for change: Simon, G. E., VonKorff, M., Rutter, C., & Wagner,
Research on child and adolescent mental health. E. (2000). Randomised trial of monitoring,
Rockville, MD: National Institute of Mental feedback, and management of care by telephone
Health. Available from http://www.nimh.nih.gov to improved treatment of depression in primary
care. British Medical Journal, 320, 550-554.
New Freedom Commission on Mental Health.
(2003). Achieving the promise: Transforming Stahl, S. M., & Grady, M. M. (2004). A critical
mental health care in America. Final Report. review of atypical antipsychotic utilization:
(DHHS Publication. No. SMA-03-3832). Comparing monotherapy with polypharmacy
Rockville, MD: Author. and augmentation. Current Medicinal
Chemistry, 11, 313-327.
Ng, C. H., Chong, S., Lambert, T., Fan, A.,
Hackett, L., Mahendran, R., et al., (2005). Taylor, A. C., Bond, G. R., Tsai, J., Howard, P. B.,
An inter-ethnic comparison study of clozapine El-Mallakh, P., Finnerty, M., et al. (2009). Scales
dosage, clinical response and plasma levels. to evaluate quality of medication management:
International Clinical Psychopharmacology. Development and psychometric properties.
20(3) 163-168. Administration and Policy in Mental Health
and Mental Health Services Research. Published
Parks, J. J. (2007). Implementing practice online February 27, 2009. DOI 10.1007/s10488-
guidelines: Lessons from public mental health 009-0209-z
settings. Journal of Clinical Psychiatry, 68(Suppl
4), 45-48. Teague, G. R., Drake, R. E., & Ackerson, T.
(1995). Evaluating use of continuous treatment
Peters, T. J., & Waterman, R. H. (1982). In search teams for persons with mental illness and
of excellence. New York: Harper & Row. substance abuse. Psychiatric Services, 46,
689-695.
Rush, A. J., Jr., First, M. B., & Blacker, D. (Eds.).
(2008). Handbook of Psychiatric Measures
(2nd ed.). Arlington, VA: American Psychiatric
Publishing, Inc.

The Evidence 21 References

Toprac, M. G., Dennehy, E. B., Carmody, T. J., Weinmann, S., Koesters, M., & Becker, T. (2007).
Crismon, M. L., Miller, A. L., Trivedi, M., et al. Effects of implementation of psychiatric
(2006). Implementation of the Texas Medication guidelines on provider performance and patient
Algorithm Project patient and family education outcome: Systematic review. Acta Psychiatrica
program. Journal of Clinical Psychiatry, 67, Scandinavica, 115, 420-433.
1362-1372.
Wells, K. B., Sherbourne, C., Schoenbaum,
U.S. Department of Health and Human Services. M., Duan, N., Meredith, L., Unutzer, J., et
(1999). Mental health: A report of the Surgeon al. (2000). Impact of disseminating quality
General. Rockville, MD: U.S. Department of improvement programs for depression in
Health and Human Services, Substance Abuse managed primary care: A randomized controlled
and Mental Health Services Administration, trial. Journal of the American Medical
Center for Mental Health Services, and National Association, 283, 212-220.
Institutes of Health, National Institute of
Mental Health. Worrall, G., Angel, J., Chaulk, P., Clarke, C.,
& Robbins, M. (1999). Effectiveness of
U.S. Department of Health and Human Services. an educational strategy to improve family
(2001). Mental health: Culture, race, and physicians’ detection and management of
ethnicity—A supplement to Mental health: depression: A randomized controlled trial.
A report of the Surgeon General. Rockville, Canadian Medical Association Journal,
MD: U.S. Department of Health and Human 161, 37-40.
Services, Substance Abuse and Mental Health
Services Administration, Center for Mental Young, A. S., Sullivan, G., Burnam, M. A., &
Health Services. Brook, R. H. (1998). Measuring the quality of
outpatient treatment for schizophrenia. Archives
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, of General Psychiatry, 55, 611-617.
J. P., Citrome, L., McEvoy, J. P., et al. (2002).
Clozapine, olanzapine, risperidone, and Young, G. J., Mohr, D. C., Meterko, M., Seibert,
haloperidol in the treatment of patients with M. N., & McGlynn, G. (2006). Psychiatrists’
chronic schizophrenia and schizoaffective self-reported adherence to evidence-based
disorder. American Journal of Psychiatry, 159, prescribing practices in the treatment of
255–262; erratum, 159, 2132. schizophrenia. Psychiatric Services, 57, 130-132.

Weiden, P. J. (2007). Discontinuing and switching

antipsychotic medications: Understanding the
CATIE schizophrenia trial. Journal of Clinical
Psychiatry, 68(Suppl 1), 12-19.

References 22 The Evidence

 The Evidence

Acknowledgments

The materials included in the MedTEAM KIT were developed through the
University of Texas at San Antonio. In partnership with many other collaborators,
including clinicians, researchers, consumers, family members, and administrators,
and operating under the direction of the Substance Abuse and Mental Health
Services Administration, Center for Mental Health Services, these materials were
evaluated and revised.

We wish to acknowledge the many people who contributed to all aspects of this
project. In particular, we wish to acknowledge the contributors and consultants
on the next few pages.

The Evidence 23 Acknowledgments

 SAMHSA Center for Mental Health Services, Oversight Committee

Michael English (deceased) Sushmita Shoma Ghose

Division of Service and Systems Improvement Community Support Programs Branch
Rockville, Maryland Division of Service and Systems Improvement
Rockville, Maryland
Neal B. Brown
Community Support Programs Branch Patricia Gratton
Division of Service and Systems Improvement Division of Service and Systems Improvement
Rockville, Maryland Rockville, Maryland

Sandra Black Betsy McDonel Herr

Community Support Programs Branch Community Support Programs Branch
Division of Service and Systems Improvement Division of Service and Systems Improvement
Rockville, Maryland Rockville, Maryland

Crystal R. Blyler Larry D. Rickards

Community Support Programs Branch Homeless Programs Branch
Division of Service and Systems Improvement Division of Service and Systems Improvement
Rockville, Maryland Rockville, Maryland

Pamela Fischer Ken Thompson

Homeless Programs Branch SAMHSA Center for Mental Health Services
Division of Service and Systems Improvement Rockville, Maryland
Rockville, Maryland

Co-leaders

Tom Mellman Troy Moore

Dartmouth Medical School University of Texas at San Antonio
Hanover, New Hampshire San Antonio, Texas

Alexander Miller
University of Texas Health Science Center
at San Antonio
San Antonio, Texas

Acknowledgments 24 The Evidence

 Contributors

Neal Adams Catherine Craig

California Institute of Mental Health University of Texas Health Science Center
Soquel, California at San Antonio
San Antonio, Texas
Charity Appell
Ascutney, Vermont Lynn Crismon
University of Texas College of Pharmacy
Robert Arizpe San Antonio, Texas
San Antonio State Hospital
San Antonio, Texas Albana Dassori
University of Texas Health Science Center
Kate Bell at San Antonio
Humboldt County Department of Mental Health San Antonio, Texas
Humboldt, California
Robert Drake
Crystal R. Blyler Dartmouth Psychiatric Research Center
Community Support Programs Branch Concord, New Hampshire
Division of Service and Systems Improvement
Rockville, Maryland Paul Eisenhauer
San Antonio, Texas
Gary Bond
Indiana University, Purdue University Susan Essock
at Indianapolis The Mount Sinai School of Medicine
Indianapolis, Indiana New York, New York

Neal Brown Anita Everett

Community Support Programs Branch SAMHSA
Division of Service and Systems Improvement Rockville, Maryland
Rockville, Maryland
Molly Finnerty
Barbara Burns New York State Office of Mental Health
Duke University School of Medicine New York, New York
Durham, North Carolina
Vijay Ganju
Michael J. Cohen National Association of State Mental Health
National Alliance on Mental Illness (NAMI) Program Directors Research Institute
Concord, New Hampshire Alexandria, Virginia

The Evidence 25 Acknowledgments

Sushmita Shoma Ghose Carolee Moore
Community Support Programs Branch Center for Health Care Services
Division of Service and Systems Improvement San Antonio, Texas
Rockville, Maryland
Mona Neaderhiser
Cindy Hopkins University of Texas Health Science Center
Texas Department of Mental Health and Mental at San Antonio
Retardation San Antonio, Texas
San Antonio, Texas
Joseph Parks
Howard H. Goldman Missouri Department of Mental Health
University of Maryland School of Medicine Jefferson City, Missouri
Baltimore, Maryland
Frank Perez
Paul G. Gorman San Antonio, Texas
Dartmouth Psychiatric Research Center
Lebanon, New Hampshire Ernest Quimby
Howard University
Pat Howard Washington, D.C.
University of Kentucky
Lexington, Kentucky Steven Shon
Texas Department of Mental Health and
Karin Kalk Mental Retardation
California Institute of Mental Health Austin, Texas
Ladera Ranch, California
Gus Sicard
H. Stephen Leff Center for Healthcare Services
The Evaluation Center at the Human Services San Antonio, Texas
Research Institute
Cambridge, Massachusetts Steven Steury
Department of Mental Health
Natalie Maples Washington, D.C.
University of Texas at San Antonio
San Antonio, Texas Patricia Suppes
Stanford University School of Medicine
Steven Marder Stanford, Connecticut
University of California at Los Angeles
Los Angeles, CA Ken Thompson
SAMHSA Center for Mental Health Services
Noel Mazade Rockville, Maryland
National Association of State Mental Health
Program Directors Research Institute
Alexandria, Virginia

Acknowledgments 26 The Evidence

Marcia Toprac Madhukar Trivedi
Texas Department of Mental Health University of Texas at San Antonio
and Mental Retardation San Antonio, Texas
San Antonio, Texas
Dawn Velligan
William Torrey University of Texas at San Antonio
Dartmouth Medical School San Antonio, Texas
Hanover, New Hampshire
Ellen Weissman
Laura Van Tosh The Mount Sinai School of Medicine
Olympia, Washington New York, New York

Consultants to the National Implementing Evidence-Based Practices Project

Dan Adams Nancy L. Bolton

St. Johnsbury, Vermont Cambridge, Massachusetts

Diane C. Alden Patrick E. Boyle

New York State Office of Mental Health Case Western Reserve University
New York, New York Cleveland, Ohio

Lindy Fox Amadio Mike Brady

Dartmouth Psychiatric Research Center Adult and Child Mental Health Center
Concord, New Hampshire Indianapolis, Indiana

Diane Asher Ken Braiterman

The University of Kansas National Alliance on Mental Illness (NAMI)
Lawrence, Kansas Concord, New Hampshire

Stephen R. Baker Janice Braithwaite

University of Maryland School of Medicine Snow Hill, Maryland
Baltimore, Maryland
Michael Brody
Stephen T. Baron Southwest Connecticut Mental Health Center
Department of Mental Health Bridgeport, Connecticut
Washington, D.C.
Mary Brunette
Deborah R. Becker Dartmouth Psychiatric Research Center
Dartmouth Psychiatric Research Center Concord, New Hampshire
Lebanon, New Hampshire

The Evidence 27 Acknowledgments

Sharon Bryson Judy Cox
Ashland, Oregon New York State Office of Mental Health
New York, New York
Barbara J. Burns
Duke University School of Medicine Harry Cunningham
Durham, North Carolina Dartmouth Psychiatric Research Center
Concord, New Hampshire
Jennifer Callaghan
The University of Kansas Gene Deegan
School of Social Welfare University of Kansas
Lawrence, Kansas Lawrence, Kansas

Kikuko Campbell Natalie D. L.ca

Indiana University–Purdue University Indiana University–Purdue University
Indianapolis, Indiana Indianapolis, Indiana

Linda Carlson Robert E. Drake

University of Kansas Dartmouth Psychiatric Research Center
Lawrence, Kansas Lebanon, New Hampshire

Diana Chambers Molly Finnerty

Department of Health Services New York State Office of Mental Health
Burlington, Vermont New York, New York

Alice Claggett Laura Flint

University of Toledo College of Medicine Dartmouth Evidence Based Practices Center
Toledo, Ohio Burlington, Vermont

Marilyn Cloud Vijay Ganju

Department of Health and Human Services National Association of State Mental Health
Concord, New Hampshire Program Directors Research Institute
Alexandria, Virginia
Melinda Coffman
The University of Kansas Susan Gingerich
Lawrence, Kansas Narberth, Pennsylvania

Jon Collins Phillip Glasgow

Office of Mental Health and Addiction Services Wichita, Kansas
Salem, Oregon
Howard H. Goldman
Laurie Coots University of Maryland School of Medicine
Dartmouth Psychiatric Research Center Baltimore, Maryland
Lebanon, New Hampshire

Acknowledgments 28 The Evidence

Paul G. Gorman Hea-Won Kim
Dartmouth Psychiatric Research Center Indiana University–Purdue University
Lebanon, New Hampshire Indianapolis, Indiana

Gretchen Grappone David A. Kime

Concord, New Hampshire Transcendent Visions and Crazed Nation Zines
Fairless Hills, Pennsylvania
Eileen B. Hansen
University of Maryland School of Medicine Dale Klatzker
University of Maryland, Baltimore The Providence Center
Providence, Rhode Island
Kathy Hardy
Strafford, Vermont Kristine Knoll
Dartmouth Psychiatric Research Center
Joyce Hedstrom Lebanon, New Hampshire
Courtland, Kansas
Bill Krenek
Lon Herman Department of Mental Health
Department of Mental Health Columbus, Ohio
Columbus, Ohio
Rick Kruszynski
Lia Hicks Case Western Reserve University
Adult and Child Mental Health Center Cleveland, Ohio
Indianapolis, Indiana
H. Stephen Leff
Debra Hrouda The Evaluation Center at the Human Services
Case Western Reserve University Research Institute
Cleveland, Ohio Cambridge, Massachusetts

Bruce Jensen Treva E. Lichti

Indiana University–Purdue University National Alliance on Mental Illness (NAMI)
Indianapolis, Indiana Wichita, Kansas

Clark Johnson Wilma J. Lutz

Salem, New Hampshire Ohio Department of Mental Health
Columbus, Ohio
Amanda M. Jones
Indiana University–Purdue University Anthony D. Mancini
Indianapolis, Indiana New York State Office of Mental Health
New York, New York
Joyce Jorgensen
Department of Health and Human Services Paul Margolies
Concord, New Hampshire Hudson River Psychiatric Center
Poughkeepsie, New York

The Evidence 29 Acknowledgments

Tina Marshall Britt J. Myrhol
University of Maryland School of Medicine New York State Office of Mental Health
Baltimore, Maryland New York, New York

Ann McBride (deceased) Bill Naughton

Oklahoma City, Oklahoma Southeastern Mental Health Authority
Norwich, Connecticut
William R. McFarlane
Maine Medical Center Nick Nichols
Portland, Maine Department of Health
Burlington, Vermont
Mike McKasson
Adult and Child Mental Health Center Bernard F. Norman
Indianapolis, Indiana Northeast Kingdom Human Services
Newport, Vermont
Alan C. McNabb
Ascutney, Vermont Linda O’Malia
Oregon Health and Science University
Meka McNeal Portland, Oregon
University of Maryland School of Medicine
Baltimore, Maryland Ruth O. Ralph
University of Southern Maine
Ken Minkoff Portland, Maine
ZiaLogic
Albuquerque, New Mexico Angela L. Rollins
Indian University–Purdue University
Michael W. Moore Indianapolis, Indiana
Office of Mental Health and Addiction Services
Salem, Oregon Tony Salerno
New York State Office of Mental Health
Roger Morin New York, New York
The Center for Health Care Services
San Antonio, Texas Diana C. Seybolt
University of Maryland School of Medicine
Lorna Moser Baltimore, Maryland
Indiana University–Purdue University
Indianapolis, Indiana Patricia W. Singer
Santa Fe, New Mexico
Kim T. Mueser
Dartmouth Psychiatric Research Center Mary Kay Smith
Concord, New Hampshire University of Toledo
Toledo, Ohio

Acknowledgments 30 The Evidence

Diane Sterenbuch Boyd J. Tracy
Bethesda, Maryland Dartmouth Psychiatric Research Center
Lebanon, New Hampshire
Bette Stewart
University of Maryland School of Medicine Laura Van Tosh
Baltimore, Maryland Olympia, Washington

Steve Stone Joseph A. Vero

Mental Health and Recovery Board National Alliance on Mental Illness (NAMI)
Ashland, Ohio Aurora, Ohio

Maureen Sullivan Barbara L. Wieder

Department of Health and Human Services Case Western Reserve University
Concord, New Hampshire Cleveland, Ohio

Beth Tanzman Mary Woods

Vermont Department of Health Westbridge Community Services
Burlington, Vermont Manchester, New Hampshire

Greg Teague
University of Southern Florida
Tampa, Florida

The Evidence 31 Acknowledgments

 Special thanks

Special thanks to the Robert Wood Johnson Foundation for its generous contribution.

Production, editorial, and graphics support

Carolyn Boccella Bagin Chandria Jones

Center for Clear Communication, Inc. Westat
Rockville, Maryland Rockville, Maryland

Jason Davis Glynis Jones

Westat Westat
Rockville, Maryland Rockville, Maryland

Sushmita Shoma Ghose Tina Marshall

Westat Westat
Rockville, Maryland Rockville, Maryland

Julien P. Hofberg Mary Anne Myers

Westat Westat
Rockville, Maryland Rockville, Maryland

Acknowledgments 32 The Evidence

HHS Publication No. SMA-10-4548
Printed 2010
28610.0510.8712010401